<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336826</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-048-DMD</org_study_id>
    <secondary_id>2020-000980-21</secondary_id>
    <nct_id>NCT04336826</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to &lt;2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)</brief_title>
  <official_title>An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to &lt;2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety, tolerability, and pharmacokinetics (PK) in male&#xD;
      children with nmDMD aged ≥6 months to &lt;2 years treated daily for 24 weeks with orally&#xD;
      administered ataluren 10, 10, and 20 milligrams/kilogram (mg/kg) (morning, mid-day, and&#xD;
      evening dose, respectively).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who complete the 24-week treatment period in this study will be offered&#xD;
      participation to a follow-up extension period for at least 52 weeks from the date of first&#xD;
      administration of ataluren in this parent study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve From Time 0 to 24 Hours (AUC0-24) of Ataluren</measure>
    <time_frame>Predose, 1, 2, 3, and 4 hours post morning and mid-day doses; and pre-dose, 1, 2, 3, 4 and 12 (before the next day morning dose) hours post evening dose at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve From Time 0 to 6 Hours (AUC0-6) of Ataluren</measure>
    <time_frame>Predose, 1, 2, 3, and 4 hours post morning and mid-day doses; and pre-dose, 1, 2, 3, 4 and 12 (before the next day morning dose) hours post evening dose at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Ataluren</measure>
    <time_frame>Predose, 1, 2, 3, and 4 hours post morning and mid-day doses; and pre-dose, 1, 2, 3, 4 and 12 (before the next day morning dose) hours post evening dose at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Maximal Plasma Concentration (Tmax) of Ataluren</measure>
    <time_frame>Predose, 1, 2, 3, and 4 hours post morning and mid-day doses; and pre-dose, 1, 2, 3, 4 and 12 (before the next day morning dose) hours post evening dose at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Trough Concentration (Ctrough) of Ataluren</measure>
    <time_frame>Pre-morning dose at Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Nonsene Mutation Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <description>Ataluren will be administered as per the dose and schedule specified in the arm.</description>
    <arm_group_label>Ataluren</arm_group_label>
    <other_name>PTC124</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ≥7.5 kilograms (kg)&#xD;
&#xD;
          -  Diagnosis of duchenne muscular dystrophy (DMD) based on an elevated serum creatine&#xD;
             kinase and genotypic evidence of dystrophinopathy.&#xD;
&#xD;
          -  Documentation of the presence of a nonsense mutation of the dystrophin gene as&#xD;
             determined by gene sequencing prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any drug or device investigation or whose sibling is currently&#xD;
             participating in a blinded portion of another ataluren study or received an&#xD;
             investigational drug within three months prior to the Screening Visit or who&#xD;
             anticipate participating in any other drug or device clinical investigation or&#xD;
             receiving any other investigational drug within the duration of this study.&#xD;
&#xD;
          -  Expectation of a major surgical procedure during the study period.&#xD;
&#xD;
          -  Known hypersensitivity to any of the ingredients or excipients of the study drug&#xD;
             (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone&#xD;
             XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate).&#xD;
&#xD;
          -  Ongoing use of the following drugs:&#xD;
&#xD;
               1. Systemic aminoglycoside therapy and/or intravenous (IV) vancomycin.&#xD;
&#xD;
               2. Coumarin-based anticoagulants (for example, warfarin), phenytoin, tolbutamide, or&#xD;
                  paclitaxel.&#xD;
&#xD;
               3. Inducers of UGT1A9 (for example, rifampicin), or substrates of OAT1 or OAT3 (for&#xD;
                  example, ciprofloxacin, adefovir, oseltamivir, aciclovir, captopril, furosemide,&#xD;
                  bumetanide, valsartan, pravastatin, rosuvastatin, atorvastatin, pitavastatin).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinay Penematsa</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy Corporate Relations</last_name>
    <phone>1-866-562-4620</phone>
    <email>medinfo@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Han C. Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

